We have recently commenced as new Tuberculosis (TB) study.
The study is funded by a £1.8m funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme with Chief Investigator Professor Wei Shen Lim from the NIHR Nottingham BRC and is being led at Nottingham by Dr Harry Pick.
Reintroduction of anti-tuberculosis therapy following drug-induced liver injury: a randomised controlled trial
What is the study about?
In the UK, TB is routinely treated with a combination of four medicines, this is referred to as 4-drug treatment. Most patients can successfully complete their treatment course without any problems. Unfortunately, in some cases, the treatment can begin to cause damage to the liver, this is called drug-induced liver injury (DILI). To protect the liver and encourage it to recover, the TB treatment is stopped.
The aim of the TB-DILI trial is to identify the safest and most effective way to restart treatment for patients that have had their Tuberculosis (TB) treatment stopped due to experiencing drug-induced liver injury (DILI). We will also determine which re-introduction strategy is most cost-effective for the NHS.
What are we trying to find out?
To determine if reintroduction of a non-pyrazinamide (Z)-containing anti-tuberculosis therapy (ATT) regimen results in a lower drug-induced liver injury (DILI) recurrence rate compared to a Z-containing ATT regimen in adults who have experienced an episode of DILI when being treated for active tuberculosis (TB).
For More Information: